(MedPage Today) — In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention (PCI).
4D-ACS trial investigators…
Source link : https://www.medpagetoday.com/meetingcoverage/europcr/115729
Author :
Publish date : 2025-05-22 21:19:00
Copyright for syndicated content belongs to the linked Source.
